RCEL vs. ATRI, KIDS, EMBC, FNA, PLSE, OFIX, SIBN, IRMD, BVS, and SRDX
Should you be buying AVITA Medical stock or one of its competitors? The main competitors of AVITA Medical include Atrion (ATRI), OrthoPediatrics (KIDS), Embecta (EMBC), Paragon 28 (FNA), Pulse Biosciences (PLSE), Orthofix Medical (OFIX), SI-BONE (SIBN), Iradimed (IRMD), Bioventus (BVS), and Surmodics (SRDX). These companies are all part of the "surgical & medical instruments" industry.
Atrion (NASDAQ:ATRI) and AVITA Medical (NASDAQ:RCEL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, community ranking, media sentiment, earnings, dividends and profitability.
AVITA Medical has a consensus target price of $24.60, suggesting a potential upside of 155.98%. Given Atrion's higher possible upside, analysts clearly believe AVITA Medical is more favorable than Atrion.
Atrion has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Comparatively, AVITA Medical has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500.
Atrion has higher revenue and earnings than AVITA Medical. AVITA Medical is trading at a lower price-to-earnings ratio than Atrion, indicating that it is currently the more affordable of the two stocks.
Atrion has a net margin of 10.60% compared to Atrion's net margin of -88.41%. AVITA Medical's return on equity of 7.75% beat Atrion's return on equity.
Atrion received 56 more outperform votes than AVITA Medical when rated by MarketBeat users. However, 68.22% of users gave AVITA Medical an outperform vote while only 54.89% of users gave Atrion an outperform vote.
In the previous week, Atrion had 9 more articles in the media than AVITA Medical. MarketBeat recorded 11 mentions for Atrion and 2 mentions for AVITA Medical. Atrion's average media sentiment score of 0.93 beat AVITA Medical's score of 0.22 indicating that AVITA Medical is being referred to more favorably in the news media.
66.2% of Atrion shares are owned by institutional investors. Comparatively, 27.7% of AVITA Medical shares are owned by institutional investors. 22.8% of Atrion shares are owned by company insiders. Comparatively, 1.8% of AVITA Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Atrion beats AVITA Medical on 11 of the 17 factors compared between the two stocks.
Get AVITA Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for RCEL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AVITA Medical Competitors List
Related Companies and Tools
